

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 2/6/1962  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**JAK2 (V617F) Mutation by ddPCR, Quantitative**

ARUP test code 3003751

JAK2 QNT, Source Bone Marrow

JAK2 V617F Percent Mutated Alleles 0.0 %

JAK2 V617F Mutation by PCR Not Detected

There is no evidence of the JAK2 V617F mutation by ddPCR analysis. This result does not entirely exclude the possibility that a point mutation exists in the sample below the detection limit of the test (0.2 percent), nor does it exclude mutations other than the V617F mutation.

This result has been reviewed and approved by [REDACTED]

**INTERPRETIVE INFORMATION:** JAK2 (V617F) Mutation by ddPCR, Quant  
This assay is designed to detect the point mutation c.1849G>T (V617F) of the JAK2 gene. JAK2 V617F mutations are present in patients with myeloproliferative neoplasms.  
Methodology: DNA from whole blood or bone marrow specimens is amplified in an allele-specific droplet digital PCR (ddPCR) multiplex reaction targeting the JAK2 c.1849G>T single nucleotide mutation encoding the V617F mutation. Results are reported as a percent mutated alleles versus wild type alleles. The limit of detection for this assay is 0.2 percent mutated alleles.  
Limitations: Variants in genes other than JAK2 are not detected. Variant alleles of JAK2 other than V617F (c.1849G>T) are not reported. Samples with JAK2 V617F mutations below the limit of reporting may not be detected.  
Results of this test must always be interpreted in the context of morphologic and other relevant data, and should not be used alone for a diagnosis of malignancy. This test is not intended to detect minimal residual disease.  
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**H=High, L=Low, \*=Abnormal, C=Critical**

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
JAK2 QNT, Source	23-038-104856	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
JAK2 V617F Percent Mutated Alleles	23-038-104856	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
JAK2 V617F Mutation by PCR	23-038-104856	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at: